Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00371150 · ClinicalTrials.gov registry record · Phase 4
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection
A Phase 4 study of Hepatitis B Infection, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 131
- Enrollment target
- 20
- Study locations
NCT00371150: Completed Phase 4 study of Hepatitis B Infection, sponsored by Bristol-Myers Squibb.
NCT00371150 is a Phase 4 study of Hepatitis B Infection that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 131 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00371150, a Phase 4 study of Hepatitis B Infection, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 131 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.
Primary Outcome
HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. HBV DNA \< 50 IU/mL = approximately \<300 copies/mL.
Conditions Studied
Interventions
- DRUG Entecavir
Study Locations (20)
Florida
- University Of Miami - Miami
- Empire International Research - Miami
Massachusetts
- Brigham And Women'S Hospital - Boston
- L L C Bda The Research Institute - Springfield
New York
- Va New York Harbor Healthcare System - New York
- Westchester Digestive Disease Group, Llp - Yonkers
São Paulo
- Local Institution - Campinas
- Local Institution - Sao Paulo - Sp
Alabama
- Alabama Liver & Digestive Specialists (Alds) - Montgomery
Arizona
- University Of Arizona - Tucson
District of Columbia
- George Washington University Medical Center - Washington D.C.
Illinois
- University Of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 4 |
What the finished NCT00371150 record still lists
NCT00371150 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Hepatitis B Infection appearing as the primary indexed condition, and to 1 intervention - of which Entecavir is the first listed.
NCT00371150 names 20 study sites across 16 states, led by Florida, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00371150 about?
NCT00371150 is a clinical study titled "Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection". The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.
What is the current status of trial NCT00371150?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 131 participants. The study started on 2006-11. Estimated completion is 2011-03.
What conditions does trial NCT00371150 study?
This clinical trial studies the following conditions: Hepatitis B Infection.
What interventions are being tested in trial NCT00371150?
The interventions under investigation include: Entecavir (DRUG).
Who is sponsoring clinical trial NCT00371150?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00371150 being conducted?
This trial has 20 study locations across Alabama, Arizona, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00371150's enrollment target sits among peer trials
131 619th of 2000 higher than 1,379 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia